Jan 26 |
Aptose Biosciences prices 4.9M shares at $1.71 in underwritten public offering
|
Jan 26 |
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
|
Dec 9 |
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
|
Dec 4 |
Aptose Biosciences files to sell ordinary shares, warrants
|
Nov 30 |
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
|
Nov 10 |
Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call Transcript
|
Nov 10 |
Aptose Biosciences Inc. (APTO) Q3 2023 Earnings Call Transcript
|
Nov 9 |
Aptose Biosciences GAAP EPS of -$1.76 beats by $0.22
|
Nov 9 |
Aptose Reports Results for the Third Quarter 2023
|
Nov 8 |
Aptose Biosciences Q3 2023 Earnings Preview
|